---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-002862"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:18:44.665143+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# VYNE updates corporate presentation with previously announced Phase 1a data for VYN202

## Summary
- Phase 1a data for VYN202 and pipeline program updates included in presentation; data was previously announced.
- Presentation posted on company website and filed as Exhibit 99.1 on January 13, 2025.
- No new financial results or material events disclosed in this 8-K filing.

## SEC filing metadata
- accession: 0001104659-25-002862
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000110465925002862/0001104659-25-002862-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000110465925002862/tm252956d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-002862
- JSON: https://secwatch.observer/filing/0001104659-25-002862.json
- Plain text: https://secwatch.observer/filing/0001104659-25-002862.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.